Oxford Vaccine Progress

AstraZeneca is now reporting its AZD1222 COVID-19 mRNA vaccine could be available as early as January of next year. Long favored in the epidemiological community as one of the more likely effective and safe vaccines in development by several major pharmaceutical companies, AstraZeneca’s teaming with Oxford University is now in late-stage trials in Britain and the U.S., as well as other countries, to determine the vaccine’s efficacy and safety.